Reflecting on Organon’s biosimilars interests as he spoke at the J.P. Morgan Healthcare Conference, CEO Kevin Ali both underlined the segment’s current significant as a growth driver for the company, while also alluding to uncertainty over the long-term future of the biosimilars business.
In general, Ali observed, Organon’s biosimilars segment was healthy, having grown at a “double-digit rate” – by 28% as reported and by 25% excluding the impacts of foreign currency – to $424m in 2021